The Head of Innovation & Technology at Invest Hong Kong (InvestHK), Mr Andy Wong, will embark on a duty visit to the United States from tomorrow (June 16) to June 20 to engage with local biotech stakeholders, start-ups, investors and media with the aim of attracting more business and investment into Hong Kong.
     
     A delegation of 16 Hong Kong life science and health technology companies will be joining InvestHK and the Hong Kong Science and Technology Parks Corporation (HKSTP) to the BIO International Convention 2025, the world's premier biotechnology event, running June 16 to 19 (Boston time) at the Boston Convention & Exhibition Center. This joint effort underscores the strong partnership between InvestHK and the HKSTP to promote Hong Kong's vibrant biotech ecosystem on a global stage.
     
     At the Hong Kong pavilion, the delegation will showcase the city's unrivalled advantages and opportunities for American biotech companies seeking to expand into the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) and Asia Pacific. InvestHK will connect with global industry pioneers, sharing insights and forging partnerships to spotlight Hong Kong's strategic strengths as a biotech powerhouse. Through dynamic presentations, one-on-one discussions, and interactive showcases, InvestHK will highlight the city's cutting-edge ecosystem, which is tailored to empower American biotech firms to thrive in Asia's fast-growing markets.
     
     Associate Director-General of Investment Promotion at InvestHK Mr Charles Ng said, "Amid a climate of global economic uncertainty and unprecedented challenges, businesses are increasingly focused on resilience, diversification, and innovation. Hong Kong, as a global biotech hub and one of the world's leading fundraising hubs for life science and biotech, offers unique advantages for American biotechnology companies. These include a top-tier academic research and talent pool, world-class research and development infrastructure, financial strength, robust intellectual property protection, high-quality clinical trial data and strong government commitment. All these make Hong Kong an ideal location for establishing a regional headquarters to expand into the GBA and Asia-Pacific region."
           
     The Chief Executive Officer of the HKSTP, Mr Albert Wong, said, "The United States is the world's largest healthcare market. For technology companies to succeed in the US market, it is essential to understand how the local healthcare system operates and effectively communicates the unique value of their R&D capabilities to investors. The goal of this visit goes beyond seeking immediate investment - it is also about building long-term bridges between innovation ecosystems; offering a globally connected environment to exchange ideas, collaborate and scale. I expect the delegation will begin to see tangible results within the next 12 to 18 months."

     Hong Kong's biotech sector is driven by innovations such as smart hospitals and telehealth, addressing rising healthcare demands with sustainable solutions. The Hong Kong Special Administrative Region Government is enhancing the city's capabilities through the establishment of the InnoLife Healthtech Hub in the Hong Kong-Shenzhen Innovation and Technology Park. The 2024 Policy Address also introduced a HK$10 billion I&T Industry-Oriented Fund to channel investment into strategic industries, including life and health technology.
     
     The GBA presents significant opportunities for American biotech firms. Designated GBA healthcare institutions can utilise Hong Kong-registered drugs and medical devices approved for public hospitals, with 51 drugs and 63 medical devices having been allowed by the Guangdong Provincial Medical Products Administration as of April 30, 2025. Additionally, the Listing Rules reform by the Hong Kong Exchanges and Clearing Limited has positioned it as a leading exchange for biotech initial public offerings, enabling pre-revenue biotech companies to list on the main board and access robust capital markets.
     
     InvestHK has seen strong momentum in attracting innovation and technology (I&T) companies to establish or expand their presence in the city. In 2024, the number of I&T companies assisted by InvestHK rose to 120, up from 82 in 2023, making it the top-performing sector among all sectors supported by the department. This growth reflects both the increasing global confidence in Hong Kong's innovation ecosystem and the city's strategic role as a springboard for I&T businesses looking to access Mainland China and Asia-Pacific markets.
     
     The BIO International Convention 2025 unites over 20 000 global industry leaders, representing virtually the entire biotechnology ecosystem. In an era of transformative discovery, biotechnology is revolutionising healthcare, agriculture, and environmental sustainability, offering hope and solutions to global challenges.

Ends/Sunday, June 15, 2025
Issued at HKT 10:00

NNNN